Advances in the diagnosis and treatment of hepatitis C virus infection in patients with and without HIV infection;Avances en el diagnóstico y tratamiento de la infección por el VHC en pacientes con y sin infección por el VIH

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 23, Issue 1, 2005, Pages 32-40

  Laguno, Montse ^a   Sánchez Tapias, José Ma ^a   Murillas, Javier ^a   Forns, Xavier ^a   Blanco, José L ^a   Martínez, Esteban ^a   Larrousse, María ^a   León, Agathe ^a   Loncá, Montse ^a   Milinkovic, Ana ^a   Miró, José M ^a   García, Felipe ^a   Gatell, José Ma ^a   Mallolas, Josep ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Chronic hepatitis C; HCV therapy; HIV HCV co infection

Indexed keywords

INTERFERON; PEGINTERFERON; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN;

ALOPECIA; ANOREXIA; APATHY; ARTHRALGIA; ASTHENIA; ATAXIA; AUTOIMMUNE DISEASE; BLOOD; BODY WEIGHT DISORDER; CHRONIC HEPATITIS; CONCENTRATION DIFFICULTY; CONFUSION; CONVULSION; DELIRIUM; DEPRESSION; DIARRHEA; DISEASE COURSE; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; EXTRAPYRAMIDAL SYMPTOM; FEVER; GRANULOCYTOPENIA; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRIGLYCERIDEMIA; IMMUNOPATHOLOGY; INSOMNIA; IRRITABILITY; LIVER BIOPSY; MENTAL DEFICIENCY; MIGRAINE; MIXED INFECTION; MORBIDITY; MORTALITY; MYALGIA; NAUSEA; PERCUTANEOUS TRANSMISSION; PSORIASIS; PSYCHOSIS; RASH; REVIEW; SANITATION; SARCOIDOSIS; SEXUAL TRANSMISSION; SIDE EFFECT; SUICIDE; SUICIDE ATTEMPT; THROMBOCYTOPENIA; TREATMENT INDICATION; VERTICAL TRANSMISSION; VIRUS TRANSMISSION; WEIGHT REDUCTION;

EID: 20044369545     PISSN: 0213005X     EISSN: None     Source Type: Journal    
DOI: 10.1157/13070408     Document Type: Review

References (74)

1. WHO: Hepatitis CV: global prevalence (updated). Wkly epidemiol Rec 2000;6:35-47.
2. Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C virus prevalence among patients coinfected with human immunodeficiency virus: a cross-sectional analysis of the U.S. Adult AIDS Clinical Trials Group. Clin Infect Dis 2002;34:831-7.
3. Bonacini M, Puoti M. Hepatitis C in patients with human immunodeficiency virus infection: diagnosis, natural history, meta-analysis of sexual and vertical transmission, and therapeutic issues. Arch Intern Med 2000;160:3365-73.
4. Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposures to HBV, HCV, and HIV and Recommendations for Postexposure Prophylaxis. MMWR Morb Mortal Wkly Rep 2001;50:1-52.
5. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med 1996;334:1685-90.
6. Eyster ME, Alter HJ, Aledort LM, Quan S, Hatzalds A, Goedert JJ. Heterosexual co-transmission of hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Ann Intern Med 1991;115:764-8.
7. Thomas DL, Villano SA, Riester KA, Hershow R, Mofenson LM, Landesman SH, et al. Perinatal transmission of hepatitis C virus from human immunodeficiency virus type 1-infected mothers. Women and Infants Transmission Study. J Infect Dis 1998;177:1480-8.
8. Resti M, Azzari C, Galli L, Zuin G, Giacchino R, Bortolotti F, et al. Maternal drug use is a preeminent risk factor for mother-to-child hepatitis C virus transmission: results from a multicenter study of 1372 mother-infant pairs. J Infect Dis 2002;185:567-72.
9. Seeff LB. Natural History of hepatitis C. Hepatology 1997;26(Suppl 1):21-8.
10. Freeman AJ, Dore GJ, Law MG, Thorpe M, Von Overbeck J, Lloyd AR, et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 2001;34(4 Pt 1):809-16.
11. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997;112:463-72.
12. Monga HK, Rodríguez-Barradas MC, Breaux K, Khattak K, Troisi CL, Vélez M, et al. Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 33:240-7.
13. Bica I, McGovern B, Dhar R, Stone D, McGowan K, Scheib R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001;32:492-7.
14. Martín-Carbonero L, Soriano V, Valencia E, García-Samaniego J, López M, González-Lahoz J. Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients. AIDS Res Hum Retroviruses 2001;17:1467-71.
15. Cacoub P, Geffray L, Rosenthal E, Perronne C, Veyssier P, Raguin G, et al. Mortality among human immunodeficiency virus-infected patients with cirrhosis or hepatocellular carcinoma due to hepatitis C virus in French Departments of Internal Medicine/Infectious Diseases, in 1995 and 1997. Clin Infect Dis 2001;32:1207-14.
16. Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, Galai N, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000;284:450-6.
17. Mehta SH, Cox A, Hoover DR,Wang XH, Mao Q, Ray S, et al. Protection against persistence of hepatitis C. Lancet 2002;359:1478-83.
18. Benhamou Y, Bochet M, Di Martino V, Charlotte F, Azria F, Coutellier A, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999;30:1054-8.
19. Soto B, Sánchez-Quijano A, Rodrigo L, Del Olmo JA, García-Bengoechea M, Hernández-Quero J, et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol 1997;26:1-5.
20. Graham CS, Baden LR, Yu E, Mrus JM, Carnie J, Heeren T, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001;33:562-9.
21. Di Martino V, Rufat P, Boyer N, Renard P, Degos F, Martinot-Peignoux M, et al. The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study. Hepatology 2001;34:1193-9.
22. García-Samaniego J, Rodríguez M, Berenguer J, Rodríguez-Rosado R, Carbó J, Asensi V, et al. Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C. Am J Gastroenterol 2001;96:179-83.
23. Perez-Olmeda M, García-Samaniego J, Soriano V. Hepatitis C viremia in HIV-HCV coinfected patients having immune restoration with HAART. AIDS 2000;14:212.
24. Cooper CL, Cameron DW. Review of the effect of highly active antiretroviral therapy on hepatitis C virus (HCV) RNA levels in human immunodeficiency virus and HCV coinfection. Clin Infect Dis 2002;35:873-9.
25. Benhamou Y, Di Martino V, Bochet M, Colombet G, Thibault V, Liou A, et al. Factors affecting liver fibrosis in human immunodeficiency virus and hepatitis C virus co-infected patients: impact of protease inhibitor therapy. Hepatology 2001;34:283-7.
26. Greub G, Ledergerber B, Battegay M, Grob P, Perrin L, Furrer H, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 2000;356:1800-5.
27. De Luca A, Bugarini R, Cozzi Lepri A, Puoti M, Girardi E, Antinori A, et al. Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects. Arch Intern Med 2002;162:2125-32.
28. Dorrucci M, Pezzotti P, Phillips AN, Lepri AC, Rezza G. Coinfection of hepatitis C virus with human immunodeficiency virus and progression to AIDS. Italian Seroconversion Study. J Infect Dis 1995;172:1503-8.
29. Sulkowski MS, Moore RD, Mehta SH, Chaisson RE, Thomas DL. Hepatitis C and progression of HIV disease. JAMA 2002;288:199-206.
30. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000;283:74-80.
31. Martínez E, Blanco JL, Arnáiz JA, Pérez-Cuevas JB, Mocroft A, Cruceta A, et al. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS 2001;15:1261-8.
32. Núñez M, Ríos P, Martín-Carbonero L, Pérez-Olmeda M, González-Lahoz J, Soriano V. Role of hepatitis C virus genotype in the development of severe transaminase elevation after the introduction of antiretroviral therapy. J Acquir Immune Defic Syndr 2002;30:65-8.
33. John M, Flexman J, French MA. Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: an immune restoration disease? AIDS 1998;12:2289-93.
34. Barbaro G, Di Lorenzo G, Asti A, Ribersani M, Belloni G, Grisorio B, et al. Hepatocellular mitochondrial alterations in patients with chronic hepatitis C: ultrastructural and biochemical findings. Am J Gastroenterol 1999;94:2198-205.
35. Chamot E, Hirschel B, Wintsch J, Robert CF, Gabriel V, Déglon JJ, et al. Loss of antibodies against hepatitis C virus in HIV-seropositive intravenous drug users. AIDS 1990;4:1275-7.
36. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997;349:825-32.
37. Saadeh S, Cammell G, Carey WD, Younossi Z, Barnes D, Easley K. The role of liver biopsy in chronic hepatitis C. Hepatology 2001;33:196-200.
38. Soriano V, Puoti M, Sulkowski M, Mauss S, Cacoub P, Cargnel A, et al. Care of patients with hepatitis C and HIV co-infection. AIDS 2004;18:1-12.
39. Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. Hepatology 2002;36(5 Suppl 1):S47-S56.
40. Vento S, Garofano T, Renzini C, Cainelli F, Casali F, Ghironzi G, et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med 1998;338:286-90.
41. Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. International Interferon-alpha Hepatocellular Carcinoma Study Group. Lancet 1998;351:1535-9.
42. Uberti-Foppa C, De Bona A, Morsica G, Galli L, Gallotta G, Boeri E, et al. Pretreatment of chronic active hepatitis C in patients coinfected with HIV and hepatitis C virus reduces the hepatotoxicity associated with subsequent antiretroviral therapy. J Acquir Immune Defic Syndr 2003;33:146-52.
43. Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000;343:1666-72.
44. Lindsay KL, Trepo C, Heintges T, Shiffman ML, Gordon SC, Hoefs JC, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001;34:395-403.
45. Heathcote EJ, Shiffman ML, Cooksley WGE, Dusheiko GM, Lee SS, Balart L, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000;343:1673-80.
46. Manns MP, McHutchison JG, Gordon S, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared to interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001;358:958-965.
47. Fried MW, Shiffman M, Reddy RK, Smith C, Marinos G, Goncales FL, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
48. Hadziyannis SJ, Sette H, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon alfa-2a and ribavirin combination therapy in chronic hepatitis C. A randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140;346-55.
49. Zuezem S, Hultcrantz R, Bourliere M, Goeser T, Marcellin P, Sánchez-Tapias J, et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004;40:993-9.
50. McHutchison J, Manns M, Harvey J, Albrecht JK. Adherence to therapy enhances sustained response in chronic hepatitis C patients receiving PEG-Interferon alfa-2b plus ribavirin. J Hepatol 2001;34(Suppl 1):2-3.
51. Boyer N, Marcellin P, Degott C, Degos F, Saimot AG, Erlinger S, et al. Recombinant interferon-alpha for chronic hepatitis C in patients positive for antibody to human immunodeficiency virus. Comité des Anti-Viraux.. J Infect Dis 1992;165:723-6.
52. Marriott E, Navas S, Del Romero J, García S, Castillo I, Quiroga JA, et al. Treatment with recombinant alpha-interferon of chronic hepatitis C in anti-HIV-positive patients. J Med Virol 1993;40:107-11.
53. Soriano V, García-Samaniego J, Bravo R, González J, Castro A, Castilla J, et al. Interferon alpha for the treatment of chronic hepatitis C in patients infected with human immunodeficiency virus. Hepatitis-HIV Spanish Study Group Clin Infect Dis 1996;23:585-91.
54. Nasti G, Di Gennaro G, Rizzardini G, Cadorin L, Ticelli U. Chronic hepatitis C in HIV-coinfected patients: feasibility and efficacy of interferon-alpha 2b and ribavirin combination therapy. J Acquir Immune Defic Syndr 2001;26:299-300.
55. Sauleda S, Juárez A, Esteban JI, Altisent C, Ruiz I, Puig L, et al. Interferon and ribavirin combination therapy for chronic hepatitis C in HIV-infected patients with congenital coagulation disorders. Hepatology 2001;34: 1035-40.
56. Zylberberg H, Benhamou Y, Lagneaux JL, Landau A, Chaix ML, Fontaine H, et al. Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report. Gut 2000;47:694-7.
57. Landau A, Batisse D, Piketty C, Duong Van Huyen JP, Bloch F, Belec L, et al. Long-term efficacy of combination therapy with interferon-alpha 2b and ribavirin for severe chronic hepatitis C in HIV-infected patients. AIDS 2001;15:2149-55.
58. Torriani FJ, Rodríguez-Torres M, Rockstroh JK, Lissen E, González-García J, Lazzarin A, et al. APRICOT Study Group. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004;351:438-50.
59. Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE, et al. AIDS Clinical Trials Group A5071 Study Team. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004;351:451-9.
60. Perrone C, Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel F, et al. P and ANRS HCO2-RIBAVIC study group. 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, UA, 8-11 february 2004; abstract 117LB.
61. Laguno M, Murillas J, Blanco JL, Martínez E, Miquel R, Sánchez-Tapias JM, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS 2004;18:27-36.
62. Pérez-Olmeda M, Núñez M, Romero M, González J, Castro A, Arribas JR, et al. Pegylated IFN-alpha-2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. AIDS 2003;17:1023-8.
63. Moreno L, Quereda C, Moreno A, Pérez-Elias MJ, Antela A, Casado J, et al. Pegylated interferon alpha-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients. AIDS 2004;18:67-73.
64. Torriani FJ, Ribeiro RM, Gilbert TL, Schrenk UM, Clauson M, Pacheco DM, et al. Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) dynamics during HCV treatment in HCV/HIV coinfection. J Infect Dis 2003;188:1498-507.
65. EASL consensus statement. EASL international consensus conference on hepatitis C. J Hepatol 1999;30:956-61.
66. National Institutes of Health. Consensus development conference statement. Management of hepatitis C: 2002. Hepatology 2002;36:S3-S20.
67. Poynard T, McHutchison J, Goodman Z, Ling MH, Albrecht J. Is an "A la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? Hepatology 2000;31:211-8.
68. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virological response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003;38;645-52.
69. Soriano V, Núñez M, Camino N, Maida I, Barreiro P, Romero M, et al. Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin. Antivir Ther 2004;9:505-9.
70. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002;36:S237-S44.
71. Laguno M, Blanch J, Murillas J, Blanco JL, León A, Lonca M, et al. Depressive symptoms after initiation of interferon therapy in human immunodeficiency virus-infected patients with chronic hepatitis C. Antivir Ther. (En prensa.)
72. Dieterich DT. Treatment of hepatitis C and anemia in human immunodeficiency virus-infected patients. J Infect Dis 2002;185(Suppl 2:)S128-S37.
73. Lafeuillade A, Hittinger G, Chadapaud S. Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet 2001;357:280-1.
74. Salmon-Céron D, Chauvelot-Moachon L, Abad S, Silbermann B, Sogni P. Mitochondrial toxic effects and ribavirin. Lancet 2001;357:1803-4.